Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 975 of 3499 entries
View as:

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03866382 Org: User:
Start: 05/13/19 End: 02/28/26 Due: 02/28/27

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Phase: N/A Priority: Normal
NCT ID: NCT06507748 Org: User:
Start: 07/02/25 End: 05/01/26 Due: 05/01/27

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Phase: N/A Priority: Normal
NCT ID: NCT04267848 Org: User:
Start: 06/16/20 End: 12/15/25 Due: 12/15/26

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT05675410 Org: User:
Start: 05/11/23 End: 04/28/31 Due: 04/28/32

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase: N/A Priority: Normal
NCT ID: NCT06066138 Org: User:
Start: 07/02/25 End: 01/31/27 Due: 01/31/28

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06161558 Org: User:
Start: 07/02/25 End: 11/16/27 Due: 11/16/28

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Phase: N/A Priority: Normal
NCT ID: NCT05058651 Org: User:
Start: 06/28/22 End: 10/01/28 Due: 10/01/29

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Phase: N/A Priority: Normal
NCT ID: NCT06064097 Org: User:
Start: 06/25/24 End: 12/31/26 Due: 12/31/27

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04181060 Org: User:
Start: 12/28/20 End: 12/31/26 Due: 12/31/27

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

Phase: N/A Priority: Normal
NCT ID: NCT05440409 Org: User:
Start: 10/14/21 End: 10/29/24 Due: 10/29/25

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT06303193 Org: User:
Start: 07/02/25 End: 01/01/35 Due: 01/01/36

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06058377 Org: User:
Start: 11/27/23 End: 05/31/26 Due: 05/31/27

Helicobacter Pylori Genome Project (HpGP)

Phase: N/A Priority: Normal
NCT ID: NCT02788214 Org: User:
Start: 07/27/16 End: 05/15/20 Due: 05/15/21

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04981509 Org: User:
Start: 06/10/22 End: 12/31/27 Due: 12/31/28

Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00002587 Org: User:
Start: 09/30/94 End: 12/31/00 Due: 12/31/01

Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias

Phase: N/A Priority: Normal
NCT ID: NCT05969002 Org: User:
Start: 08/25/23 End: 04/30/26 Due: 04/30/27

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00030693 Org: User:
Start: 12/31/01 End: - Due: -

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT06577441 Org: User:
Start: 06/12/25 End: 03/01/27 Due: 03/01/28

Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00098579 Org: User:
Start: 10/31/04 End: - Due: -

Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00006171 Org: User:
Start: 08/07/00 End: 06/29/12 Due: 06/29/13

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00450255 Org: User:
Start: 06/30/07 End: 01/31/11 Due: 01/31/12

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00328861 Org: User:
Start: 05/31/06 End: 04/30/09 Due: 04/30/10

Specimens From Normal Controls

Phase: N/A Priority: Normal
NCT ID: NCT00341211 Org: User:
Start: 04/11/96 End: 12/01/10 Due: 12/01/11

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04345913 Org: User:
Start: 03/01/21 End: 05/07/26 Due: 05/07/27

Avelumab for People With Recurrent Respiratory Papillomatosis

Phase: N/A Priority: Normal
NCT ID: NCT02859454 Org: User:
Start: 08/06/16 End: 09/15/21 Due: 09/15/22